Advertisement
Advertisement
BVS
Bioventus Inc. Class A Common Stock
13.91
USDSponsored
+0.06
+0.47%
Aug 12, 16:00 UTC -4
Closed
Pre-Market
13.91
0.00
0.00%
BVS Earnings Reports
Positive Surprise Ratio
BVS beat 17 of 23 last estimates.
74%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$150.77M
/$0.17
Implied change from Q2 26 (Revenue/ EPS)
-1.59%
/-22.73%
Implied change from Q3 25 (Revenue/ EPS)
+8.74%
/+13.33%
Bioventus Inc. Class A Common Stock earnings per share and revenue
On Aug 05, 2026, BVS reported earnings of 0.22 USD per share (EPS) for Q2 26, beating the estimate of 0.21 USD, resulting in a 0.82% surprise. Revenue reached 153.21 million, compared to an expected 157.20 million, with a -2.54% difference. The market reacted with a +13.71% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 0.17 USD, with revenue projected to reach 150.77 million USD, implying an decrease of -22.73% EPS, and decrease of -1.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Silence Therapeutics Plc - ADR
Report Date
Aug 10, 2026 For Q2 26
Estimate
-Actual
-$0.26
Surprise
-
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
Heron Therapeutics, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.01
Actual
-$0.03
Surprise
-394.12%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Bioventus Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bioventus Inc. Class A Common Stock reported EPS of $0.22, beating estimates by 0.82%, and revenue of $153.21M, -2.54% below expectations.
How did the market react to Bioventus Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 13.71%, changed from $13.42 before the earnings release to $15.26 the day after.
When is Bioventus Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Bioventus Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Bioventus Inc. Class A Common Stock is expected to report EPS of $0.17 and revenue of $150.77M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement